Assessment of therapy with continuous subcutaneous insulin infusion in an academic diabetes clinic.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Justen W Rudolph, Irl B Hirsch

Abstract

To assess the results of continuous subcutaneous insulin infusion (CSII) therapy in patients with type 1 diabetes mellitus, especially relative to glycemic control and rate of discontinuation of insulin pump therapy. A retrospective review of the medical records of 107 patients with type 1 diabetes who were receiving CSII at the Diabetes Care Center at the University of Washington Medical Center was performed to evaluate clinical outcomes. All patients considering CSII therapy participated in a class to learn the details of insulin pump treatment. The mean age of our patient population was 36.0 +/- 10.4 years (mean value +/- standard deviation). The mean duration of diabetes at the initiation of insulin pump therapy was 17.0 +/- 9.1 years. The mean duration of CSII use was 36.1 +/- 25.5 months (median, 26.2 months). Insulin lispro was used by 89.7% of the patients. Six patients (5.6%) discontinued CSII therapy after a mean of 19.1 +/- 14.7 months for a variety of reasons. Despite no significant difference in home blood glucose monitoring (number of tests per day) before initiation of CSII, mean hemoglobin A1c levels decreased from 7.6% to 7.1% (P<0.0001), and the occurrence of severe hypoglycemic episodes decreased 73.8% (P = 0...Continue Reading

References

Jan 1, 1988·The American Journal of the Medical Sciences·D S BellR S Clements
Feb 1, 1994·Diabetes Research and Clinical Practice·E SchifferdeckerH Schatz
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Jan 1, 1996·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·A PfütznerJ Beyer
Dec 24, 1997·Diabetic Medicine : a Journal of the British Diabetic Association·M EggerP Diem
Apr 17, 1998·Diabetic Medicine : a Journal of the British Diabetic Association·S SchmaussR Landgraf
Jan 6, 2001·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·D S Bell, F Ovalle

❮ Previous
Next ❯

Citations

Jan 14, 2005·The New England Journal of Medicine·Irl B Hirsch
Jun 11, 2010·Diabetes Technology & Therapeutics·Satish K Garg
Nov 22, 2005·Expert Opinion on Drug Delivery·Garry M Steil, Kerstin Rebrin
Jan 28, 2015·Contemporary Clinical Trials·Kenneth IzuoraGuillermo Umpierrez
Dec 7, 2007·Primary Care·Russell D White
Jun 26, 2003·Diabetic Medicine : a Journal of the British Diabetic Association·P Scuffham, L Carr
Jan 28, 2009·Diabetes/metabolism Research and Reviews·Daniela BruttomessoAldo Baritussio
May 6, 2015·Indian Journal of Endocrinology and Metabolism·Subhash Kumar Wangnoo
May 31, 2016·The American Journal of the Medical Sciences·Kenneth E IzuoraGuillermo E Umpierrez
Feb 12, 2008·Revista clínica española·J Sáez de la FuenteA Herreros de Tejada López-Coterilla
Jan 30, 2004·Diabetes Care·Stephen ClementUNKNOWN American Diabetes Association Diabetes in Hospitals Writing Committee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.